A near-infrared fluorescent probe and its application in preparing early diagnostic reagents for Alzheimer's disease
Patent Information
- Application Number
- CN202211641199.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-20
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2042-12-20
AI Technical Summary
[0036] The present invention designs a near-infrared fluorescent probe based on the "D-π-A" configuration. The probe can target and bind to amyloid-β. After binding to amyloid-β, the fluorescence signal is significantly enhanced, and the emission wavelength will appear. Blue shift phenomenon. The near-infrared fluorescent probe provided by the invention has the characteristics of emitting wavelength located in the near-infrared region, specifically targeting β-amyloid protein, and having good selectivity, and is of great significance for the research and development of early diagnostic probes for Alzheimer's disease.
Smart Images

Figure CN116239482B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of near-infrared fluorescent probes and relates to a near-infrared fluorescent probe and an application thereof in the preparation of an early diagnosis reagent for Alzheimer's disease. Background Art
[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not be necessarily regarded as an admission or any form of suggestion that the information constitutes the prior art already known to those skilled in the art.
[0003] At present, the β-amyloid protein (Amyloid-β, Aβ) cascade hypothesis is generally considered to be one of the pathogenic mechanisms of Alzheimer's disease (AD). Therefore, Aβ plaques formed by Aβ deposition and accumulation are considered to be an important marker in the pathogenesis of AD, and being able to directly display Aβ plaques in vivo is helpful for the early diagnosis of AD. Near-infrared fluorescence imaging has been widely studied due to its high safety, long fluorescence lifetime, high penetration depth, low autofluorescence interference, low cost, and short detection cycle. Therefore, a new near-infrared fluorescent probe for early diagnosis of AD is needed. Summary of the invention
[0004] In order to address the deficiencies of the prior art, the purpose of the present invention is to provide a near-infrared fluorescent probe and its use in the preparation of an early diagnostic reagent for Alzheimer's disease. The near-infrared fluorescent probe provided by the present invention is a type of D-π-A type fluorescent probe, which has an emission wavelength in the near-infrared region and can specifically detect β-amyloid protein. After binding to β-amyloid protein, the fluorescent signal is significantly enhanced, and can be used for the detection of β-amyloid protein and the early diagnosis of Alzheimer's disease.
[0005] In order to achieve the above object, the technical solution of the present invention is:
[0006] On the one hand, a near-infrared fluorescent probe, whose chemical structure is shown in formula (I),
[0007]
[0008] Wherein, n = 0 to 2;
[0009] R1 is C1-C5 alkyl or C1-C5 hydroxyalkyl; R2 is C1-C5 alkyl or C1-C5 hydroxyalkyl;
[0010] W is a thiophene ring, a furan ring, a benzene ring, a naphthalene ring or a quinoline ring;
[0011] R3 is The C1-C5 hydroxyalkyl group represents a C1-C5 alkyl group substituted by a hydroxy group.
[0012] Further, the compound shown below is included,
[0013]
[0014] On the other hand, a method for preparing the above-mentioned near-infrared fluorescent probe comprises the following steps: dissolving the compound represented by formula (II) in a protic solvent, and then reacting the compound represented by formula (III) with the compound represented by formula (III) under the catalysis of a base to produce the compound represented by formula (I) by Knoevenagel reaction.
[0015]
[0016] R3 is
[0017] Alternatively, the method comprises subjecting the compound represented by formula (X) and the compound represented by formula (VII) to a wittig reaction under alkaline conditions to obtain the compound represented by formula (I);
[0018]
[0019] R3 is
[0020] Alternatively, the compound represented by formula (VIII) is reacted with malononitrile under alkaline conditions by Wittig reaction to obtain the compound represented by formula (I) according to the following reaction formula;
[0021]
[0022] R3 is
[0023] Furthermore, the preparation method of the compound represented by formula (II) is: subjecting the compound represented by formula (IV) to a wittig reaction with (1,3-dioxolane-2-yl)methyltriphenylphosphonium bromide in an aprotic solvent in the presence of a base and a phase transfer catalyst, and then removing the acetal to obtain;
[0024] Alternatively, the above process is included, and the product after removing the acetal is used as a raw material to replace the compound represented by formula (IV) and repeat the above process
[0025]
[0026] When R1 or R2 is (C1-C4) hydroxyalkyl, 3,4-dihydropyran is used to protect -OH during the wittig reaction, i.e., to convert it into -OTHP group, by dissolving the compound represented by formula (II) in anhydrous dichloromethane, adding 3,4-dihydropyran and pyridinium p-toluenesulfonate, and reacting at room temperature for 24 to 48 hours. The room temperature in the present invention refers to the temperature of the indoor environment.
[0027] In a third aspect, a composition comprises the above-mentioned near-infrared fluorescent probe and a pharmaceutically acceptable salt thereof.
[0028] The pharmaceutically acceptable salt of the present invention is a salt formed with an acid, and the acid may be an inorganic acid (such as hydrochloric acid, sulfuric acid, etc.) or an organic acid (such as acetic acid, citric acid, methanesulfonic acid, etc.).
[0029] In a fourth aspect, a preparation comprises the above-mentioned near-infrared fluorescent probe or a pharmaceutically acceptable salt or composition thereof and a pharmaceutically acceptable carrier.
[0030] The carrier of the present invention is lecithin, serum protein, glycerol and the like.
[0031] A fifth aspect is a use of the above-mentioned near-infrared fluorescent probe, composition and / or preparation in the preparation of a reagent for detecting β-amyloid protein aggregates.
[0032] A sixth aspect is the use of the above-mentioned near-infrared fluorescent probe, composition and / or preparation in the preparation of an early diagnostic reagent for Alzheimer's disease.
[0033] In a seventh aspect, a kit for early diagnosis of Alzheimer's disease comprises the above-mentioned near-infrared fluorescent probe and a solvent.
[0034] The solvent of the present invention can be phosphate buffer solution, physiological saline, etc.
[0035] The beneficial effects of the present invention are:
[0036] The present invention designs a near-infrared fluorescent probe based on the "D-π-A" configuration. The probe can target and bind to amyloid-β protein. After binding to amyloid-β protein, the fluorescence signal is significantly enhanced, and the emission wavelength will show a blue shift phenomenon. The near-infrared fluorescent probe provided by the present invention has the characteristics of emission wavelength in the near-infrared region, specific targeting of amyloid-β protein, and good selectivity, which is of great significance for the research and development of early diagnosis probes for Alzheimer's disease. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.
[0038] Figure 1 The fluorescent probe and Aβ in the embodiment of the present invention 1-42 Fluorescence spectra of aggregates before and after incubation;
[0039] Figure 2 In the embodiment of the present invention, the fluorescent probes are respectively 1-42 Fluorescence spectra of aggregates before and after incubation with BSA; DETAILED DESCRIPTION
[0040] It should be noted that the following detailed descriptions are exemplary and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.
[0041] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit exemplary embodiments according to the present invention. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprising" and / or "including" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.
[0042] In order to enable those skilled in the art to more clearly understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below in conjunction with specific embodiments.
[0043] Unless otherwise specified, the experimental methods used in the following examples are all conventional methods in the art, and the reagents, equipment and raw materials used are all commercially available; the specific experimental conditions and methods not specified in the examples are all based on conventional experimental conditions or the experimental conditions recommended by the manufacturer.
[0044] Example 1: Preparation of intermediates
[0045] Preparation of compound 2
[0046] Pure compound 1 (1.0 g) was dissolved in anhydrous dichloromethane (20 mL), and (1,3-dioxolane-2-yl)methyltriphenylphosphine bromide (3.5 g), anhydrous potassium carbonate (3.7 g) and a trace of 18-crown ether-6 were added to the system and refluxed for 12-24 h. After the reaction was completed, the mixture was filtered and the solvent was evaporated. The residue was dissolved in tetrahydrofuran, an excess of hydrochloric acid (2 M) was added, and the mixture was stirred at room temperature for 30 min. Saturated potassium carbonate solution was then added dropwise to adjust the pH value of the system to neutral, and the mixture was extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, the solvent was evaporated, and the yellow solid compound 2 was obtained by silica gel column chromatography (PE: EA).
[0047] Compound 2: MS m / z 176 (M+1); 1 H NMR(600MHz,Chloroform-d)δ9.58(d,J=7.9Hz,1H),7.44(d,J=8.9Hz,2H),7.37(d ,J=15.6Hz,1H),6.68(d,J=8.9Hz,2H),6.53(dd,J=15.6,7.9Hz,1H),3.04(s,6H).
[0048]
[0049] Preparation of compound 3
[0050] Pure compound 2 (40 mg) was dissolved in anhydrous dichloromethane (10 mL), and (1,3-dioxolane-2-yl)methyltriphenylphosphine bromide (147 mg), anhydrous potassium carbonate (126 mg) and a trace of 18-crown ether-6 were added to the system, and the reaction was refluxed for 12-24 h. After the reaction was completed, the mixture was filtered and the solvent was evaporated. The residue was dissolved in tetrahydrofuran, excess hydrochloric acid (2 M) was added, and the mixture was stirred at room temperature for 30 min. Saturated potassium carbonate solution was then added dropwise to adjust the pH value of the system to neutral, extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, the solvent was evaporated, and purified by silica gel column chromatography (PE: EA) to obtain an orange solid compound 3.
[0051] Compound 3: MS m / z 202 (M+1); 1 H NMR(400MHz,Chloroform-d)δ9.55(d,J=8.1Hz,1H),7.39(d,J=8.9Hz,2H),7.24(dd,J=15.0,10.9Hz,1H),6.94(d ,J=15.3Hz,1H),6.81(dd,J=15.3,10.9Hz,1H),6.67(d,J=8.8Hz,2H),6.17(dd,J=15.0,8.1Hz,1H),3.02(s,6H).
[0052]
[0053] Preparation of compound 7
[0054] Pure compound 10 (200 mg) was dissolved in anhydrous ethanol (10 ml), and NaBH4 (126 mg) was added at 0°C, and the mixture was stirred at room temperature. After the reaction was completed, water was added to quench the reaction system, and the ethanol was evaporated under reduced pressure. The system was extracted with DCM, and the organic phase was collected and dried over anhydrous Na2SO4. The solvent was evaporated and purified by silica gel column chromatography (PE:EA) to obtain a colorless oily liquid compound 11.
[0055] Pure compound 11 (3.6 g) was dissolved in anhydrous acetonitrile (50 ml), triphenylphosphine hydrobromide (10 g) was added, and the mixture was reacted at 80-90° C. for 1-3 h. After the reaction was completed, the solvent was evaporated under reduced pressure, and the mixture was purified by silica gel column chromatography (DCM:MeOH) to obtain a white solid compound 7.
[0056] Compound 11: MS m / z 178 (M+1); 1 H NMR (400MHz, Chloroform-d) δ7.22 (d, J = 8.7Hz, 2H), 6.71 (d, J = 8.7Hz, 2H), 4.53 (s, 2H), 2.93 (s, 6H), 1.84 (br s, 1H).
[0057] Compound 7: MS m / z 503 (M+1); 1 H NMR (400MHz, Chloroform-d) δ7.75-7.55(m,15H),6.77(dd,J=8.8,2.4Hz,2H),6.36(d,J=8.6Hz,2H),4.91(d,J=13.1Hz,2H),2.80(s,6H).
[0058]
[0059] Preparation of compound 8
[0060] According to the preparation steps of compound 11, compound 13 was prepared using compound 12 (100 mg, 0.57 mmol) as a raw material, and purified by silica gel column chromatography (PE:EA) to obtain colorless transparent liquid 13.
[0061] According to the method for preparing compound 7, compound 13 (540 mg, 3.05 mmol) was used as the starting material to obtain white solid 8.
[0062] Compound 13: MS m / z 178 (M+1); 1 H NMR (400MHz, Chloroform-d) δ7.29 (d, J = 8.8 Hz, 2H), 6.68 (d, J = 8.8 Hz, 2H), 6.52 (d, J = 15. 8Hz,1H),6.14-6.19(m,J=15.8,6.2Hz,1H),4.29-4.26(m,2H),2.96(s,6H),1.58(s,1H).
[0063] Compound 8: MS m / z 503 (M+1); 1H NMR (400MHz, Chloroform-d) δ7.89-7.65(m,15H),7.09(d,J=8.5Hz,2H),6.64-6.58(m,3H),5.66-5.75(m,1H),4.92(dd,J=14.8,7.4Hz,2H),2.94(6H,s).
[0064]
[0065] Preparation of compound 9
[0066] According to the preparation steps of compound 11, compound 15 was prepared using compound 14 (100 mg, 0.57 mmol) as a raw material, and purified by silica gel column chromatography (PE:EA) to obtain colorless transparent liquid 15.
[0067] According to the method for preparing compound 7, compound 15 (540 mg, 3.05 mmol) was used as the starting material to obtain white solid 9.
[0068] Compound 15: MS m / z 204 (M+1); 1 H NMR(400MHz,Chloroform-d)δ7.30(d,J=8.8Hz,2H),6.68(d,J=8.5Hz,2H),6.62(dd,J=15.5,10.3Hz,1H),6.49(d ,J=15.6Hz,1H),6.39(dd,J=15.1,10.3Hz,1H),5.87(dt,J=15.1,6.2Hz,1H),4.23(d,J=6.0Hz,2H),2.97(s,6H).
[0069] Compound 9: MS m / z 529 (M+1); 1 H NMR (400MHz, Chloroform-d) δ7.89-7.65(m,15H),7.09(d,J=8.5Hz,2H),6.64-6.58(m,3H),5.66-5.75(m,1H),4.92(dd,J=14.8,7.4Hz,2H),2.94(6H,s).
[0070]
[0071] Example 2: Preparation of Compounds A-1, A-2, and A-3
[0072] Preparation of Compound A-1
[0073] Pure compound 1 (100 mg) was dissolved in 10 mL of anhydrous ethanol, 1,3-cyclopentanedione (98 mg) and piperidine (50 μL) were added to the system, and the mixture was stirred at room temperature for reaction. After the reaction was completed, the solvent was evaporated under reduced pressure, and the mixture was purified by silica gel column chromatography (PE: EA) to obtain an orange solid compound A-1.
[0074] Compound A-1: MS m / z 230 (M+1); 1 H NMR (400MHz, Chloroform-d) δ8.56 (Br s, 2H), 7.67 (s, 1H), 6.72 (d, J = 9.3Hz, 2H), 3.17 (s, 6H), 2.75-2.71 (m, 2H), 2.68-2.64 (m, 2H).
[0075]
[0076] Preparation of compound A-2
[0077] Pure compound 2 (100 mg) was dissolved in 10 mL of anhydrous ethanol, 1,3-cyclopentanedione (84 mg) and piperidine (50 μL) were added to the system, and the mixture was stirred at room temperature for reaction. After the reaction was completed, the solvent was evaporated under reduced pressure, and the mixture was purified by silica gel column chromatography (PE:EA) to obtain a dark purple solid compound A-2.
[0078] Compound A-2: MS m / z 256 (M+1); 1 H NMR(400MHz,Chloroform-d)δ8.24(dd,J=14.8,12.5Hz,1H),7.60(d,J=8.9Hz,2H),7.54( d,J=12.4Hz,1H),7.40(d,J=14.9Hz,1H),6.68(d,J=8.9Hz,2H),3.12(s,6H),2.65(s,4H).
[0079]
[0080] Preparation of compound A-3
[0081] Pure compound 3 (50 mg) was dissolved in 10 mL of anhydrous ethanol, 1,3-cyclopentanedione (30 mg) and piperidine (25 μL) were added to the system, and the mixture was stirred at room temperature for reaction. After the reaction was completed, the solvent was evaporated under reduced pressure, and the mixture was purified by silica gel column chromatography (PE: EA) to obtain a black solid compound A-3.
[0082] Compound A-3: MS m / z 282 (M+1); 1H NMR(600MHz,Chloroform-d)δ7.83(t,J=13.4Hz,1H),7.45(d,J=13.2Hz,1H),7.43(d,J=8.4Hz,2H),7.29(dd,J=14.2 ,10.8Hz,1H),7.04(d,J=15.6Hz,1H),6.99(dd,J=15.0,10.8Hz,1H),6.68(d,J=8.4Hz,2H),3.07(s,6H),2.67(m,4H).
[0083]
[0084] Example 3: Preparation of Compounds B-1, B-2, and B-3
[0085] Preparation of compound B-1
[0086] Pure compound 1 (100 mg) was dissolved in 5 mL of anhydrous ethanol, and 1,3-indandione (147 mg) and piperidine (50 μL) were added to the system for reaction at room temperature. After the reaction was completed, the mixture was filtered and the residue was recrystallized from ethanol to obtain an orange-yellow solid compound B-1.
[0087] Compound B-1: MS m / z 278 (M+1); 1 H NMR (400MHz, Chloroform-d) δ 8.53 (d, J = 8.9 Hz, 2H), 7.93-7.90 (m, 2H), 7.78 (s, 1H), 7.72-7.70 (m, 2H), 6.74 (d, J = 9.0Hz, 2H), 3.14 (s, 6H).
[0088]
[0089] Preparation of compound B-2
[0090] Pure compound 2 (100 mg) was dissolved in 5 mL of anhydrous ethanol, and 1,3-indandione (125 mg) and piperidine (50 μL) were added to the system for reaction at room temperature. After the reaction was completed, the mixture was filtered out and the residue was recrystallized from ethanol to obtain a dark purple solid compound B-2.
[0091] Compound B-2: MS m / z 304 (M+1); 1H NMR(400MHz,Chloroform-d)δ8.27(dd,J=15.1,12.2Hz,1H),7.92-7.89(m,2H),7.73-7.71(m,2H),7.6 5(d,J=12.2Hz,1H),7.59(d,J=8.9Hz,2H),7.31(d,J=15.1Hz,1H),6.69(d,J=8.9Hz,2H),3.09(s,6H).
[0092]
[0093] Preparation of compound B-3
[0094] Pure compound 3 (30 mg) was dissolved in 5 mL of anhydrous ethanol, and 1,3-indandione (28 mg) and piperidine (10 μL) were added to the system for reaction at room temperature. After the reaction was completed, the mixture was filtered and the residue was purified by silica gel column chromatography (PE: EA) to obtain a black solid compound B-3.
[0095] Compound B-3: MS m / z 330 (M+1); 1 H NMR (600MHz, Chloroform-d) δ7.92-7.89(m,2H),7.86(d,J=13.5Hz,1H),7.74-7.72(m,2H),7.57(d,J=12.4Hz,1H),7.43(d,J=8. 2Hz, 2H), 7.20 (dd, J = 14.4, 9.7Hz, 1H), 6.99 (dd, J = 15.1, 10.1Hz, 1H), 6.95 (d, J = 15.2Hz, 1H), 6.69 (d, J = 8.2Hz, 2H), 3.04 (s, 6H).
[0096]
[0097] Example 4: Preparation of Compounds C-1, C-2, and C-3
[0098] Preparation of compound C-1
[0099] Pure compound 1 (50 mg) was dissolved in 5 mL of anhydrous ethanol, and 3-carbonyl-1,1-dicarbonylbenzothiophene (73 mg) and piperidine (25 μL) were added to the system for reaction at room temperature. After the reaction was completed, the mixture was filtered and the residue was recrystallized from ethanol to obtain an orange-yellow solid compound C-1.
[0100] Compound C-1: MS m / z 314 (M+1); 1H NMR (400MHz, Chloroform-d) δ 8.07-8.01 (m4H), 7.95 (s, 1H), 7.87-7.83 (m, 1H), 7.80-7.75 (m, 1H), 6.78 (d, J = 9.1Hz, 2H), 3.16 (s, 6H).
[0101]
[0102] Preparation of compound C-2
[0103] Pure compound 2 (50 mg) was dissolved in 5 mL of anhydrous ethanol, and 3-carbonyl-1,1-dicarbonylbenzothiophene (62 mg) and piperidine (25 μL) were added to the system to react at room temperature. After the reaction was completed, the mixture was filtered and the residue was recrystallized from ethanol to obtain a dark purple solid compound C-2.
[0104] Compound C-2: MS m / z 340 (M+1); 1 H NMR(400MHz,Chloroform-d)δ7.93-8.06(m,2H),7.82-7.87(m,1H),7.74-7.82(m,2H),7.5 8(d,J=8.9Hz,2H),7.29-7.48(m,J=26.4,14.4Hz,2H),6.69(d,J=8.9Hz,2H),3.11(s,6H).
[0105]
[0106] Preparation of compound C-3
[0107] Pure compound 3 (20 mg) was dissolved in 5 mL of anhydrous ethanol, and 3-carbonyl-1,1-dicarbonylbenzothiophene (20 mg) and piperidine (20 μL) were added to the system for reaction at room temperature. After the reaction was completed, the mixture was filtered and the residue was purified by silica gel column chromatography (PE:THF) to obtain a black solid compound C-3.
[0108] Compound C-3: MS m / z 366 (M+1); 1H NMR(600MHz,Chloroform-d)δ8.05-8.02(m,1H),8.00-7.98(m,1H),7.87-7.83(m,1H),7.79-7.76(m,1H),7.71(d,J=12.7Hz,1H),7.43(d,J=8.9Hz,2 H),7.25(dd,J=13.8,10.2Hz,1H),7.13(t,J=13.2Hz,1H),7.01(d,J=15.1 Hz, 1H), 6.97 (dd, J=15.1, 10.2Hz, 1H), 6.69 (d, J=9.0Hz, 2H), 3.11 (s, 6H).
[0109]
[0110] Example 5: Preparation of Compounds D-1, D-2, and D-3
[0111] Preparation of compound D-1
[0112] Pure compound 7 (45 mg) and pure compound 16 (233 mg) were dissolved in anhydrous DCM (10 mL), t-BuOK (39 mg) was added, and the mixture was stirred at room temperature for 2-4 h. After the reaction was completed, the solvent was evaporated under reduced pressure, and the mixture was purified by silica gel column chromatography (DCM) to obtain black solid D-1 and black solid 17.
[0113] Compound D-1: MS m / z 310 (M+1); 1 H NMR(600MHz,Chloroform-d)δ10.65(s,1H),8.18(d,J=7.5Hz,1H),8.06(d,J=16.2Hz,1H),7.77(d ,J=7.6Hz,1H),7.59(d,J=8.8Hz,2H),7.56(d,J=16.3Hz,1H),6.74(d,J=8.9Hz,2H),3.05(s,6H).
[0114]
[0115] Preparation of compound D-2
[0116] Pure compound 8 (71 mg) and pure compound 16 (27 mg) were dissolved in anhydrous DCM (10 mL), t-BuOK (24 mg) was added, and the mixture was stirred at room temperature for 2-4 h. After the reaction was completed, the solvent was evaporated under reduced pressure, and the mixture was purified by silica gel column chromatography (DCM) to obtain black solid D-2 and black solid 18.
[0117] Compound D-2: MS m / z 336 (M+1); 1 H NMR(600MHz,Chloroform-d)δ10.66(s,1H),8.15(d,J=7.5Hz,1H),8.04(dd,J=15.4,10.1Hz,1H),7.68(d,J=7.5Hz,1H),7.40(d, J=8.5Hz,2H),7.16(d,J=15.5Hz,1H),6.94(dd,J=15.4,10.1Hz,1H),6.89(d,J=15.3Hz,1H),6.69(d,J=8.4Hz,2H),3.02(s,6H).
[0118]
[0119] Preparation of compound D-3
[0120] Pure compound 9 (55 mg) and pure compound 16 (150 mg) were dissolved in anhydrous DCM (10 mL), t-BuOK (48 mg) was added, and the mixture was stirred at room temperature for 2-4 h. After the reaction was completed, the solvent was evaporated under reduced pressure, and the mixture was purified by silica gel column chromatography (DCM) to obtain black solid D-3 and black solid 19.
[0121] Compound D-2: MS m / z 362 (M+1); 1 H NMR(600MHz,Chloroform-d)δ10.66(s,1H),8.16(d,J=7.4Hz,1H),7.93(dd,J=15.4,11.2Hz,1H),7.68(d,J=7.4Hz,1H),7.3 6(d,J=7.4Hz,2H),7.13(d,J=15.4Hz,1H),6.82-6.76(m,2H),6.69-6.66(m,3H),6.58(dd,J=11.4,11.4Hz,1H),3.00(s,6H).
[0122]
[0123] Example 6: Preparation of Compounds E-1, E-2, and E-3
[0124] Preparation of compound E-1
[0125] Pure compound D-1 (14 mg) and malononitrile (5 mg) were dissolved in anhydrous EtOH (5 mL), and ammonium acetate (0.39 mg) was added and stirred at room temperature for reaction. After the reaction was completed, the solvent was evaporated under reduced pressure and purified by silica gel column chromatography (PE:EA) to obtain black solid E-1.
[0126] Compound E-1: MS m / z 384 (M+1); 1 H NMR(600MHz,Chloroform-d)δ8.77(s,1H),8.73(d,J=7.9Hz,1H),8.15(d,J=16.1Hz,1H),7.75(d ,J=8.0Hz,1H),7.60(d,J=8.8Hz,2H),7.53(d,J=16.1Hz,1H),6.74(d,J=8.8Hz,2H),3.07(s,6H).
[0127] Preparation of compound E-2
[0128] Pure compound D-2 (21 mg) and malononitrile (7 mg) were dissolved in anhydrous EtOH (5 mL), and ammonium acetate (0.46 mg) was added and stirred at room temperature for reaction. After the reaction was completed, the solvent was evaporated under reduced pressure and purified by silica gel column chromatography (PE:EA) to obtain a black solid E-2.
[0129] Compound E-2: MS m / z 358 (M+1); 1 H NMR(600MHz,Chloroform-d)δ8.77(s,1H),8.73(d,J=7.9Hz,1H),8.15(d,J=16.1Hz ,1H),7.75(d,J=8.0Hz,1H),7.60(d,J=8.8Hz,2H),7.53(d,J=16.1Hz,1H),6.74(d,J =8.8Hz,2H),3.07(s,6H).1H),7.40(d,J=8.5Hz,2H),7.16(d,J=15.5Hz,1H),6.94( dd,J=15.4,10.1Hz,1H),6.89(d,J=15.3Hz,1H),6.69(d,J=8.4Hz,2H),3.02(s,6H).
[0130]
[0131] Preparation of compound E-3
[0132] Pure compound D-3 (16 mg) and malononitrile (5 mg) were dissolved in anhydrous EtOH (5 mL), and ammonium acetate (0.34 mg) was added and stirred at room temperature for reaction. After the reaction was completed, the solvent was evaporated under reduced pressure and purified by silica gel column chromatography (DCM) to obtain black solid E-3.
[0133] Compound E-3: MS m / z 410 (M+1); 1H NMR(600MHz,Chloroform-d)δ8.76(s,1H),8.70(d,J=8.0Hz,1H),8.01(dd,J=15.3,11.2Hz,1H),7.66(d,J=7.9Hz,1H),7.36(d,J=8.8Hz, 2H),7.10(d,J=15.3Hz,1H),6.84-6.76(m,2H),6.72(d,J=11.9Hz,1H),6.68(d,J=8.9Hz,2H),6.60(dd,J=13.3,11.6Hz,1H),3.01(s,6H).
[0134]
[0135] Example 7: Evaluation of the optical properties of fluorescent probes.
[0136] Fluorescence spectroscopy property evaluation:
[0137] The probe compound prepared in the example was formulated into a mother solution with a concentration of 2 mM; after the mother solution was diluted with different solvents such as dichloromethane, tetrahydrofuran, DMSO, methanol and PBS solution, the excitation wavelength and emission wavelength of the probe compound described in the example were recorded using an RF-4600 fluorescence spectrophotometer (Hitachi, Japan). The recorded results are shown in Table 1.
[0138] Table 1. Fluorescence spectrum data of fluorescent probes
[0139]
[0140]
[0141] in:
[0142] λ em represents the maximum emission wavelength of the probe;
[0143] λ ex represents the maximum absorption wavelength of the probe;
[0144] nd means difficult to observe (weak fluorescence properties).
[0145] Table 1 shows that compounds A-2, A-3, B-2, B-3, C-2, C-3, D-2, etc. have emission wavelengths greater than 650 nm, which are in the near-infrared region and have good near-infrared fluorescence properties.
[0146] Example 8: Evaluation of biological activity of fluorescent probes
[0147] 1. Fluorescent probes and Aβ 1-42 In vitro binding assay of aggregates
[0148] The purchased Aβ 1-42 TFA monomer (purchased from Gill Biochemical Co., Ltd.) was dissolved in 1 mL of 1% ammonia water, divided into 10 sample bottles, and PBS (pH = 7.4, 1 mM) was added to one bottle to make its concentration 100 μM, and then placed in a shaker at 37°C, 100 rpm / min and incubated for 7 days.
[0149] The PBS solution of the probe was prepared according to the method described in the determination of the excitation and emission spectra of the fluorescent probe molecules prepared in the example, and the Aβ 1-42 Aggregates, so that the final concentration of the probe is 1 μM, Aβ 1-42 The final concentration of the aggregates was 5 μM. After incubation at room temperature for 10 min, the excitation and emission spectra were recorded and measured using a fluorescence spectrophotometer.
[0150] Fluorescent probes and Aβ 1-42 The fluorescence spectra of the aggregates before and after incubation are shown in Figure 2. Figure 1 shown. Figure 1 It shows that compounds A-3, B-2, B-3, C-2, C-3, etc., have a strong affinity for Aβ 1-42 After the aggregates bind, a "turn on" phenomenon occurs, and the fluorescence intensity increases significantly, making it a relatively ideal probe.
[0151] 2. In vitro binding experiment of probe and BSA
[0152] The PBS solution of the probe was prepared according to the method described in the determination of the excitation and emission spectra of the fluorescent probe molecules prepared in the example, and its fluorescence intensity was recorded; BSA (final concentration was 23 μg / mL) was added to the PBS buffer containing the fluorescent probe (final concentration was 1 μM), and the fluorescence intensity was recorded and measured using a fluorescence spectrophotometer after incubation at room temperature for 10 min.
[0153] The fluorescence spectra of the fluorescent probe before and after incubation with BSA are shown in Figure 2 As shown, Figure 2 It shows that the fluorescence intensity of probes A-3, B-3, C-3, etc., after incubation with BSA, changes very weakly, which can avoid the interference of BSA to a certain extent.
[0154] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A near-infrared fluorescent probe, characterized in that: Selected from the following compounds, ; 。 2. A method for preparing the near-infrared fluorescent probe according to claim 1, characterized in that: The method comprises dissolving the compound represented by formula (II) in a protic solvent according to the following reaction formula, and then reacting the compound represented by formula (III) with the compound represented by formula (III) under the catalysis of a base to produce the compound represented by formula (I). R3 is or ; R1 and R2 are methyl groups; W is a benzene ring.
3. The method for preparing a near-infrared fluorescent probe as claimed in claim 2, characterized in that: The preparation method of the compound represented by formula (II) is as follows: the compound represented by formula (IV) and (1,3-dioxolane-2-yl)methyltriphenylphosphonium bromide are subjected to a Wittig reaction in an aprotic solvent in the presence of a base and a phase transfer catalyst, and then the acetal is removed to obtain the compound; The above process is repeated using the product after removing the acetal as a raw material instead of the compound represented by formula (IV); 。 4. A composition, characterized in that: It comprises the near-infrared fluorescent probe according to claim 1 and a pharmaceutically acceptable salt thereof.
5. A preparation characterized in that: It comprises the near-infrared fluorescent probe according to claim 1 or a pharmaceutically acceptable salt or composition thereof and a pharmaceutically acceptable carrier.
6. Use of the near-infrared fluorescent probe according to claim 1, the composition according to claim 4 and / or the preparation according to claim 5 in the preparation of a reagent for detecting β-amyloid protein aggregates.
7. Use of the near-infrared fluorescent probe according to claim 1, the composition according to claim 4 and / or the preparation according to claim 5 in the preparation of an early diagnostic agent for Alzheimer's disease.
8. An Alzheimer's disease early diagnosis kit, characterized in that: The invention comprises the near-infrared fluorescent probe as claimed in claim 1 and a solvent.
Citation Information
Patent Citations
Diffusion or sublimation transfer imaging system
EP0175504A2
Probe for diagnosis of conformational disease
WO2007074786A1
Anti-neurodegenerative disease agent
WO2010087306A1
